[go: up one dir, main page]

CO5261604A1 - Derivados aromaticos y heteroaromaticos de 1,5-benzodiazepin-2-onas y 1,5-benzodiazepin-4-il-benzonitrilo - Google Patents

Derivados aromaticos y heteroaromaticos de 1,5-benzodiazepin-2-onas y 1,5-benzodiazepin-4-il-benzonitrilo

Info

Publication number
CO5261604A1
CO5261604A1 CO00077957A CO00077957A CO5261604A1 CO 5261604 A1 CO5261604 A1 CO 5261604A1 CO 00077957 A CO00077957 A CO 00077957A CO 00077957 A CO00077957 A CO 00077957A CO 5261604 A1 CO5261604 A1 CO 5261604A1
Authority
CO
Colombia
Prior art keywords
lower alkyl
alkoxy
alkyl
optionally substituted
lower alkoxy
Prior art date
Application number
CO00077957A
Other languages
English (en)
Inventor
Geo Adam
Alexander Alanine
Erwin Goetschi
Vincent Mutel
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5261604A1 publication Critical patent/CO5261604A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/121,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos de fórmula general I <EMI FILE="00077957_1" ID="1" IMF=JPEG >en donde X es un enlace sencillo o un grupo etinodiílo, en donde, En caso de que X sea un enlace sencillo, R1 es halógeno o fenilo que está opcionalmente sustituido con halógeno, alquilo inferior, haloalquilo inferior, alcoxi inferior, halo-alcoxilo inferior, o ciano; En caso de que X sea un grupo etinodiílo, R1 es fenilo, opcionalmente sustituido con halógeno, alquilo inferior, halo-alquilo inferior, cicloalquilo inferior, alcoxilo inferior o halo-alcoxilo inferior; R2 es halógeno; hidroxilo; alquilo inferior; halo-alquilo inferior; alcoxilo inferior; hidroximetilo; hidroxietoxilo; alcoxilo inferior-(etoxi)n (n =1 a 4); alcoxilo inferior-metilo; cianometoxilo; morfolin-4-ilo; tiomorfolin-4-ilo; 1-oxotiomorfolin-4-ilo; 1,1-dioxotiomorfolin-4-ilo; 4-oxo-piperidin-1-ilo; 4-alcoxi-piperidin-1-ilo; 4-hidroxi-piperidin-1-ilo; 4-hidroxietoxi-piperidin-1-ilo; 4-alquilo inferior-piperazin-1-ilo; alcoxicarbonilo; 2-dialquilamino etilsulfanilo-; N,N-bis alquilamino inferior alquilo inferior; carbamoilmetilo; alquilsulfonilo; alcoxilo inferior-carbonil-alquilo inferior; alquilcarboxi-alquilo inferior; carboxi-alquilo inferior; alcoxicarbonilmetilsulfanilo; carboximetilsulfanilo; 1,4-dioxa-8-aza-espiro[4.5]dec-8-il; carboxi-alcoxilo inferior; ciano-alquilo inferior; 2,3-dihidroxi-alcoxilo inferior; carbamoilmetoxilo; 2-oxo-[1,3]-dioxolan-4-il-alcoxilo inferior; (2-hidroxi-alquilo inferior)-amino alquilo inferior; hidroxicarbamoil-alcoxiIo inferior; 2,2-dimetil-tetrahidro[1,3]dioxolo[4,5c]-pirrol-5-il; alcoxilo inferior-carbamoil-alcoxilo inferior; 3R-hidroxipirrolidin-1-il; 3,4-dihidroxi-pirrolidin-1-il; 2-oxo-oxazolidin-3-il; alquilo inferior carbamoilmetoxi; ó aminocarbamoil-alcoxilo inferior; - 2 -R3 es arilo o heteroarilo de 5 ó 6 eslabones que están opcionalmente sustituidos por halógeno; ciano; nitro; azido; hidroxilo; carboxilo; morfolin-4-carbonilo; carbamoílo; tiocarbamoílo; N-hidroxicarbamoílo; trimetilsilil-etinilo; ó alquilo inferior; alcoxilo inferior; halo-alquilo inferior; 4-alquilo inferior-piperazin-1-carbonilo; alquilo inferior carbamoílo que están opcionalmente sustituidos por amino, alquilamino inferior, acilamino, oxo, hidroxilo, alcoxilo inferior, tioalquilo inferior, o carboxilo que está opcionalmente esterificado o amidado; o un heterociclo aromático opcionalmente sustituido, que puede estar opcionalmente sustituido por amino, aminoalquilo inferior, acilamino, oxo, hidroxilo, alcoxilo inferior, tioalquilo inferior, ó carboxilo que está opcionalmente esterificado o amidado, ó alquilo inferior que está opcionalmente sustituido por halógeno, amino, aminoalquilo inferior, acilamino, hidroxilo, alcoxilo inferior, tioalquilo, inferior, aciloxi, alquenoílo inferior, alquilo inferior sulfinilo, alquilo inferior sulfonilo, cicloalquilsulfinilo, cicloalquilsulfonilo, hidroxiimino, alcoxiimino, carboxilo que está opcionalmente esterificado o amidado, alquenilo inferior, oxo, ciano, carbamoiloxilo, sulfamoílo que está opcionalmente sustituido por alquilo inferior, o amido que está opcionalmente sustituido por alquilo inferior, -C(NRRAND#39)=NR" (donde R, RAND#39 y R" son hidrógeno o alquilo inferior) y sus sales de adición farmacéuticamente aceptables.
CO00077957A 1999-10-15 2000-10-12 Derivados aromaticos y heteroaromaticos de 1,5-benzodiazepin-2-onas y 1,5-benzodiazepin-4-il-benzonitrilo CO5261604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99120520 1999-10-15

Publications (1)

Publication Number Publication Date
CO5261604A1 true CO5261604A1 (es) 2003-03-31

Family

ID=8239207

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00077957A CO5261604A1 (es) 1999-10-15 2000-10-12 Derivados aromaticos y heteroaromaticos de 1,5-benzodiazepin-2-onas y 1,5-benzodiazepin-4-il-benzonitrilo

Country Status (34)

Country Link
US (1) US6407094B1 (es)
EP (1) EP1224174B1 (es)
JP (1) JP3857138B2 (es)
KR (1) KR100480320B1 (es)
CN (1) CN1195522C (es)
AR (1) AR026029A1 (es)
AT (1) ATE250039T1 (es)
AU (1) AU774451B2 (es)
BR (1) BR0014859A (es)
CA (1) CA2386974C (es)
CO (1) CO5261604A1 (es)
CZ (1) CZ20021653A3 (es)
DE (1) DE60005386T2 (es)
DK (1) DK1224174T3 (es)
EG (1) EG24079A (es)
ES (1) ES2204704T3 (es)
GC (1) GC0000263A (es)
HR (1) HRP20020259A2 (es)
HU (1) HUP0203142A3 (es)
IL (2) IL148816A0 (es)
JO (1) JO2262B1 (es)
MA (1) MA26831A1 (es)
MY (1) MY125540A (es)
NO (1) NO327817B1 (es)
NZ (1) NZ517999A (es)
PE (1) PE20010681A1 (es)
PL (1) PL357418A1 (es)
PT (1) PT1224174E (es)
RU (1) RU2259360C2 (es)
SI (1) SI1224174T1 (es)
TR (1) TR200201023T2 (es)
WO (1) WO2001029011A2 (es)
YU (1) YU26202A (es)
ZA (1) ZA200202544B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518037A (en) 1999-10-15 2004-04-30 F Benzodiazepine derivatives useful as metabotropic glutamate receptors
KR100566178B1 (ko) * 2001-04-12 2006-03-29 에프. 호프만-라 로슈 아게 mGluR2 길항물질 I로서의디하이드로-벤조[b][1,4]디아제핀-2-온 유도체
HRP20030792A2 (en) * 2001-04-12 2005-10-31 F. Hoffmann - La Roche Ag DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US6949542B2 (en) * 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
EP1539149B1 (en) * 2002-09-10 2012-01-04 Novartis AG Combinations of metabotropic glutamate receptor antagonists and their use in treating addictive disorders
JP2007516404A (ja) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ, インコーポレイテッド 光学点火されたかまたは電気点火された内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット
PL1651234T3 (pl) * 2003-07-25 2008-02-29 Hoffmann La Roche Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych
FR2862969A1 (fr) * 2003-11-28 2005-06-03 Oreal Procede de preparation de derives paraphenylenediamine a groupement pyrrolidinyle, substitue par un radical azote, et composes intermediaires
DE102004010893A1 (de) * 2004-03-06 2005-09-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP2246086A3 (en) 2004-08-12 2012-11-21 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heating unit
US7459563B2 (en) 2004-11-05 2008-12-02 Hoffmann-La Roche Inc. Process for the preparation of isonicotinic acid derivatives
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
AR059898A1 (es) * 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
ATE519751T1 (de) * 2007-04-19 2011-08-15 Hoffmann La Roche Dihydro-benzoäbüä1,4üdiazepin-2-on- sulfonamidderivate
NZ584152A (en) 2007-09-14 2011-11-25 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
TW200927731A (en) * 2007-09-14 2009-07-01 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
HRP20110278T1 (hr) 2007-09-14 2011-05-31 Ortho-Mcneil-Janssen Pharmaceuticals 1',3'-disupstituirani-4-fenil,3,4,5,6-tetrahidro-2h,1'h[1,4']bipiridinil-2'-oni
CN101815437A (zh) * 2007-09-26 2010-08-25 辛乃山医学院 氮杂胞苷类似物和其应用
ES2637794T3 (es) * 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体
MX2011003691A (es) 2008-10-16 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico.
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN101891706B (zh) * 2010-04-09 2013-05-29 复旦大学 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途
US8642626B2 (en) 2010-07-29 2014-02-04 Taisho Pharmaceutical Co., Ltd. Ethinyl-pyrazole derivative
CA2814996C (en) 2010-11-08 2019-10-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JP2012153674A (ja) * 2011-01-28 2012-08-16 Astellas Pharma Inc ジ(アリールアミノ)アリール化合物の製造方法及びその合成中間体
AR093077A1 (es) 2012-10-23 2015-05-20 Hoffmann La Roche ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3096790B1 (en) 2014-01-21 2019-07-10 Janssen Pharmaceutica, N.V. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
US9895324B2 (en) 2014-03-26 2018-02-20 University Of Kentucky Research Foundation Halogenated diarylacetylenes and methods of treating cancer
JP2017513844A (ja) 2014-04-23 2017-06-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 知的障害の処置のためのmGlu2/3アンタゴニスト
EP3154954B1 (en) 2014-06-10 2022-02-09 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CN106243050B (zh) * 2016-08-10 2019-09-06 安徽恒星制药有限公司 一种适合工业化生产氯巴占的方法
CN109836356B (zh) * 2017-11-24 2022-03-08 沈阳化工研究院有限公司 一种芳甲醚衍生物及其应用
KR102852740B1 (ko) 2018-02-02 2025-08-29 알렉스자 파마스티칼즈, 인크. 전기적 응축 에어로졸 디바이스
RU2702358C1 (ru) * 2019-06-04 2019-10-08 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Способ получения 2,2,4-триалкил-2,3-дигидро-1Н-1,5-бензодиазепинов
CN114349779B (zh) * 2021-12-29 2023-09-26 智仑超纯环氧树脂(西安)有限公司 一种改性二氧化硅颗粒除氯剂及其制备方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU437924A1 (ru) * 1972-07-28 1974-07-30 Институт Горного Дела Ан Казахской Сср Цифровой автоматический измеритель скорости распространени упругих волн
SU749836A1 (ru) * 1978-02-13 1980-07-23 Днепропетровский Ордена Трудового Красного Знамени Государственный Университет Им. 300-Летия Воссоединения Украины С Россией Способ получени 4-метил2,3-дигидро1н-1,5-бензодиазепинонов-2
AU6514296A (en) * 1995-07-31 1997-02-26 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
JP2001524468A (ja) * 1997-11-21 2001-12-04 エヌピーエス ファーマシューティカルズ インコーポレーテッド 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト

Also Published As

Publication number Publication date
AR026029A1 (es) 2002-12-26
CA2386974C (en) 2009-10-13
HUP0203142A3 (en) 2003-03-28
SI1224174T1 (en) 2003-12-31
WO2001029011A2 (en) 2001-04-26
NO327817B1 (no) 2009-09-28
IL148816A (en) 2006-10-31
ZA200202544B (en) 2003-09-23
PE20010681A1 (es) 2001-06-28
EP1224174A2 (en) 2002-07-24
RU2259360C2 (ru) 2005-08-27
DE60005386T2 (de) 2004-06-24
ES2204704T3 (es) 2004-05-01
JP2003512359A (ja) 2003-04-02
WO2001029011A3 (en) 2001-11-08
GC0000263A (en) 2006-11-01
DK1224174T3 (da) 2004-01-26
JO2262B1 (en) 2004-10-07
IL148816A0 (en) 2002-09-12
EG24079A (en) 2008-05-11
NO20021690L (no) 2002-04-10
CN1379765A (zh) 2002-11-13
CN1195522C (zh) 2005-04-06
KR20020038954A (ko) 2002-05-24
AU7910200A (en) 2001-04-30
YU26202A (sh) 2004-12-31
MY125540A (en) 2006-08-30
EP1224174B1 (en) 2003-09-17
JP3857138B2 (ja) 2006-12-13
BR0014859A (pt) 2002-07-16
PL357418A1 (en) 2004-07-26
PT1224174E (pt) 2004-01-30
US6407094B1 (en) 2002-06-18
CZ20021653A3 (cs) 2002-08-14
CA2386974A1 (en) 2001-04-26
ATE250039T1 (de) 2003-10-15
HRP20020259A2 (en) 2004-04-30
TR200201023T2 (tr) 2002-09-23
KR100480320B1 (ko) 2005-04-07
HK1051038A1 (en) 2003-07-18
HUP0203142A2 (hu) 2003-02-28
MA26831A1 (fr) 2004-12-20
DE60005386D1 (de) 2003-10-23
NZ517999A (en) 2004-07-30
NO20021690D0 (no) 2002-04-10
AU774451B2 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
CO5261604A1 (es) Derivados aromaticos y heteroaromaticos de 1,5-benzodiazepin-2-onas y 1,5-benzodiazepin-4-il-benzonitrilo
ES2319775T3 (es) Combinaciones para el tratamiento del vhc.
CO5251454A1 (es) Derivados aromaticos y heteroaromaticos de 1,5-benzodiazepin-2-onas
US7718769B2 (en) Tri-peptide hepatitis C serine protease inhibitors
EP2659893A3 (en) T cell regulation
JP2003501474A5 (es)
EA020527B1 (ru) Комбинации ингибиторов вируса гепатита с
AR035711A1 (es) Prodrogas 3&#39; de 2&#39;-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
WO2006034446A3 (en) Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
PT2353608T (pt) Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
BR9814256A (pt) Derivados de (benzodioxano, benzofurano ou benzopirano) tendo propriedades de relaxamento fúndico
JP2010510234A5 (es)
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
NO20050490L (no) 2&#39;-C-metyl-3&#39;-O-L-valinester ribofuranosylcytidin for behandling av flaviviridae infeksjoner
NO20045103L (no) Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse
JP2010510967A5 (es)
MY139418A (en) Rubber mixtures
NZ326354A (en) 3-(substituted-1-piperazinyl)-6-(substituted-1,2,4-thiadiazol-5 -yl)-pyridazine derivatives and medicaments
EA021554B1 (ru) Органические соединения и их применение для лечения hcv инфекции
EP2994140A2 (en) Methods for treating hcv infection
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
WO2004013100A3 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
WO2006054178A3 (en) Thin iol
CA3133792A1 (en) Therapeutic methods for treating hepatitis b

Legal Events

Date Code Title Description
FD Application lapsed